Acumen Pharmaceuticals Stock Forecast
NASDAQ: ABOSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 2.14 +1.83%
ABOS analyst consensus
Consensus (6 analysts)
strong_buy
Avg. price target
$7.60+261.90%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Acumen Pharmaceuticals (2026-10-08), 6 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $7.60, with a high estimate of $10.00 and a low estimate of $5.00. The average target implies upside of 261.9% from the current price of $2.10.
The spread between the highest and lowest targets is 100.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ABOS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 6 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $5.00 | +138.10% |
| Average target | $7.60 | +261.90% |
| High target | $10.00 | +376.19% |